Our Strategy

There are several key components to our strategy:

  • Develop and seek regulatory approval for our lead drug candidate, quizartinib, in relapsed/refractory AML patients who express a genetic mutation in FLT3.
  • Expand the clinical development of quizartinib in AML and other hematological disease indications.
  • Pursue strategic partnerships outside North America to accelerate development of quizartinib in indications beyond relapsed/refractory AML and expand the commercial opportunity for quizartinib.
  • Maximize strategic value by establishing a commercial capability to market, sell and distribute quizartinib in North America.
  • Leverage our core competency and proprietary chemical library to continue the discovery and development of a broad pipeline of novel drug candidates that inhibit validated kinase targets to address diseases with unmet medical need.